Mehra Golshan MD MBA
Mehra Golshan MD MBA
Deputy Chief Medical Officer, Professor of Surgery Yale School of Medicine; Executive Vice Chair of
Dirección de correo verificada de - Página principal
Citado por
Citado por
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete …
WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, ...
Journal of clinical oncology 33 (1), 13-21, 2015
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised …
S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, ...
The lancet oncology 19 (4), 497-509, 2018
Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer
SM Wong, RA Freedman, Y Sagara, F Aydogan, WT Barry, M Golshan
Annals of surgery 265 (3), 581-589, 2017
Internal mammary nodes in breast cancer: diagnosis and implications for patient management—a systematic review
RC Chen, NU Lin, M Golshan, JR Harris, JR Bellon
Journal of clinical oncology 26 (30), 4981-4989, 2008
Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis
D Calligaris, D Caragacianu, X Liu, I Norton, CJ Thompson, ...
Proceedings of the National Academy of Sciences 111 (42), 15184-15189, 2014
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
SM Tolaney, Y Boucher, DG Duda, JD Martin, G Seano, M Ancukiewicz, ...
Proceedings of the National Academy of Sciences 112 (46), 14325-14330, 2015
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival
AC Bafford, HJ Burstein, CR Barkley, BL Smith, S Lipsitz, JD Iglehart, ...
Breast cancer research and treatment 115, 7-12, 2009
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer …
JF De Los Santos, A Cantor, KD Amos, A Forero, M Golshan, JK Horton, ...
Cancer 119 (10), 1776-1783, 2013
Matched pair analyses of stage IV breast cancer with or without resection of primary breast site
B Cady, NR Nathan, JS Michaelson, M Golshan, BL Smith
Annals of surgical oncology 15, 3384-3395, 2008
Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study
Y Sagara, MA Mallory, S Wong, F Aydogan, S DeSantis, WT Barry, ...
JAMA surgery 150 (8), 739-745, 2015
Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study
A Partridge, K Adloff, E Blood, EC Dees, C Kaelin, M Golshan, J Ligibel, ...
Journal of the National Cancer Institute 100 (4), 243-251, 2008
Impact of neoadjuvant chemotherapy in stage II–III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results …
M Golshan, CT Cirrincione, WM Sikov, DA Berry, S Jasinski, TF Weisberg, ...
Annals of surgery 262 (3), 434-439, 2015
Nomogram for the prediction of having four or more involved nodes for sentinel lymph node–positive breast cancer
A Katz, BL Smith, M Golshan, A Niemierko, W Kobayashi, RA Raad, ...
Journal of clinical oncology 26 (13), 2093-2098, 2008
Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection
M Golshan, WJ Martin, K Dowlatshahi
The American surgeon 69 (3), 209-212, 2003
Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based …
Y Sagara, RA Freedman, I Vaz-Luis, MA Mallory, SM Wong, F Aydogan, ...
Journal of Clinical Oncology 34 (11), 1190-1196, 2016
Prevention and management of arm lymphedema in the patient with breast cancer.
M Golshan, B Smith
The journal of supportive oncology 4 (8), 381-386, 2006
Surgery of the primary tumor does not improve survival in stage IV breast cancer
L Dominici, J Najita, M Hughes, J Niland, P Marcom, Y Wong, B Carter, ...
Breast cancer research and treatment 129, 459-465, 2011
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data …
CE Geyer, WM Sikov, J Huober, HS Rugo, N Wolmark, J O’Shaughnessy, ...
Annals of Oncology 33 (4), 384-394, 2022
Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC+/-carboplatin and/or bevacizumab in triple-negative breast cancer …
WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, ...
Mucinous breast carcinoma: a large contemporary series
CR Barkley, JA Ligibel, JS Wong, S Lipsitz, BL Smith, M Golshan
The American journal of surgery 196 (4), 549-551, 2008
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20